AI assistant
PHARMX TECHNOLOGIES LIMITED — Board/Management Information 2026
Mar 12, 2026
65560_rns_2026-03-12_73732ba9-ac64-4e24-a933-ec1797d3d684.pdf
Board/Management Information
Open in viewerOpens in your device viewer
13 March 2026
ASX Release
Director Appointment
Pharmx Technologies Limited (ASX: PHX), (Pharmx) is pleased to announce the appointment of Mr Mark Conway as a Non-Executive Director of the Company, as nominee of Sigma Healthcare Limited (ASX: SIG), (Sigma) effective from 13 March 2026.
Mr Conway is currently Chief Strategy Officer (CSO) of Sigma Healthcare Limited and previously served as Chief Financial Officer (CFO). He has significant experience across finance, strategy and capital markets. In his current role, he is responsible for corporate strategy and growth initiatives across the Sigma Group.
Prior to joining Sigma, Mr Conway spent nearly 15 years with Fonterra in senior roles across Strategy, Commercial, Supply Chain and Consumer Operations. He has also held various finance roles with Fosters Group, Downer EDI Group and Rio Tinto.
Mr Conway brings significant financial, strategic and governance experience to the Pharmx Board, further strengthening the Company’s governance capability and will support the Company as it continues to develop and deliver critical infrastructure services to the Australian and New Zealand pharmacy sector.
Pharmx Chairman, Mr Nick England, commented: “I am delighted to welcome Mark to the Pharmx Board. He brings a wealth of experience across a range of disciplines within a number of large organisations. His strong financial and governance background allied to his strategic skills will be of great value to Pharmx as we pursue our growth agenda.”
Mr Conway commented: “I am pleased to join the Pharmx Board at an important time in its growth. Pharmx plays a critical role in connecting pharmacies and suppliers through its digital platform, and I look forward to supporting the business as it continues to strengthen its capabilities and deliver long-term value.”
The appointment follows the entry into the Strategic Alliance Agreement with Sigma as announced on 23 February 2026 and is effective from 13 March 2026.
ENDS
This announcement has been authorised for lodgement by the Board of the Company
[email protected] www.Pharmx.com.au ABN: 25 000 091 305 ACN: 000 091 305
PO BOX Q1222 Queen Victoria Building Sydney, NSW 1230 1300 724 579
For further information contact:
Tom Culver Chief Executive Officer [email protected]
About Pharmx Technologies Limited
Pharmx is ANZ’s leading pharmacy ordering platform, providing essential infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately $20 billion in transactions annually through its robust, high-availability technology platform – driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.
Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.
[email protected] www.Pharmx.com.au ABN: 25 000 091 305 ACN: 000 091 305
PO BOX Q1222 Queen Victoria Building Sydney, NSW 1230 1300 724 579